|
|
GINMU >
03 紀要 >
031 Journal of Nara Medical Association >
Vol.50 No.3 >
Please use this identifier to cite or link to this item:
http://hdl.handle.net/10564/517
|
| Title: | C型慢性肝炎に対するインターフェロン療法の治療成績(Ⅱ) |
| Other Titles: | A TRIAL OF INTERFERON TREATMENT FOR CHRONIC HEPATITIS C |
| Authors: | 上田, 重彦
城井, 啓
吉川, 佳嗣
安, 辰一
鎌田, 修
松下, 和広
山根, 佳子
池中, 康英
伯者, 徳之
簗瀬, 公嗣
山尾, 純一
菊池, 英亮
栗山, 茂樹
福居, 健一
植村, 正人
松村, 雅彦
高谷, 章
福井, 博
吉川, 正英
中野, 博 |
| Keywords: | interferon
chronic hepatitis C |
| Issue Date: | 30-Jun-1999 |
| Publisher: | 奈良医学会 |
| Citation: | Journal of Nara Medical Association Vol.50 No.3 p.215-219 |
| Abstract: | Interferon (IFN) is the only drug that has been approved by the FDA for
therapy of chronic hepatitis C. We conducted a trial of IFN therapy for chronic hepatitis
C. Eighty-eight patients with chronic hepatitis C were enrolled for the IFN trial. Either
9 million units (MU) of recombinant IFN α-2a (rIFN) or 6 MU of Iymphoblastoid IFNα
(nIFN) was administered daily for 4 weeks and then three times a week for 22 weeks. IFN
therapy was interrupted in 11 patients due to adverse reaction to IFN. In addition, a course
of observation including blood sampling was not enough to analyze IFN response in 21
subjects. Therefore, IFN response was evaluated in the remaining 56 patients. Complete
response (CR), defined as sustained normalization of serum transaminase values for more
than 6 months after the treatment, was obtained in 18 (32.1%). The CR rate in the present
IFN trial did not differ significantly from that (28.4%) in our previous IFN trial which
either 9 MU of rIFN or 3 MU of nIFN was administered daily for 2 weeks and then three
times a week for 22 weeks, suggesting that an increase in the total dose of interferon failed
to yield further benefit in patients with chronic hepatitis C. |
| URI: | http://hdl.handle.net/10564/517 |
| ISSN: | 13450069 |
| Appears in Collections: | Vol.50 No.3
|
Files in This Item:
| File |
Description |
Size | Format |
|---|
| 215-219p.C型慢性肝炎に対するインターフェロン療法の治療成績(Ⅱ).pdf | | 634Kb | Adobe PDF | View/Open |
|
All items in DSpace are protected by copyright, with all rights reserved.
|
